Second, based on a literature survey, we identified six genes [KRAS (28), STK11 (29, 30), TP53 (31), EGFR (32), ALK (32), and ROS1 (32)] associated with NSCLC patient ICI treatment responses or prognosis (hereafter, “evidence-based geneset”). This evidence concerns the gene KRAS and non-small cell lung carcinoma.